Todos Medical applauds passage of the American Recovery Act by the US Senate and House

Todos Medical Ltd (OTCQB:TOMDF) has applauded the passage of the American Recovery Act by the US Senate and House of Representatives, which it said includes funding that could support the commercialization of the company’s suite of proprietary 3CL protease diagnostic and screening tests currently in development. Todos Medical said it believes the American Recovery Act addresses many of the systemic problems with coronavirus (COVID-19) testing-related response efforts by providing $50 billion in direct funding for priorities including SARS-CoV-2 testing and genomic sequencing for variant surveillance, COVID-19 immunity profiling and monitoring in at-risk populations. “This bill will dramatically increase funding for the products and services Todos is providing to the lab marketplace, as well as products Todos is developing for SARS-CoV-2 early detection, COVID-19 quarantine release testing and COVID-19 immunity profile monitoring that will support a comprehensive, coordinated nationwide response for both vaccinated adults, as well as the unvaccinated population which includes children,” Todos Medical CEO Gerald Commissiong said in a statement.   READ: Todos Medical sales surge 50% month-over-month in December to $4.8M on demand for its COVID-19 testing products Commissiong added: “As the US begins to re-open its economy, and importantly children go back to school, the support provided by this bill will cushion the challenges we will face as we attempt to return to normalcy.” The company noted that the American Recovery Act also intends to boost funding for antiviral solutions that could complement the national vaccination plan. Pfizer is currently evaluating the safety and efficacy of the company's injectable 3CL protease inhibitor PF-00835321 in COVID-19 patients. As well, Todos said it is currently marketing the orally-available 3CL protease inhibitor Tollovid through The Alchemist’s Kitchen in New York City and intends to launch its own Todos branded Tollovid product direct to consumers in the US. Tollovid is a dietary supplement that has received a Certificate of Free Sale from the US Food and Drug Administration (FDA) and whose active ingredient is a plant extract that is tested for 3CL protease inhibition before final product formulation. The company added that it is currently marketing Tollovid as an immune-boosting product that helps to support and maintain healthy immune function, but there are currently no ongoing clinical trials of Tollovid, and Todos said it is not making any COVID-19 treatment claims for the product. Todos, though, said it intends to pursue a traditional therapeutic regulatory pathway for Tollovir in order to be able to make treatment claims in COVID-19. Contact Sean at sean@proactiveinvestors.com